Shield Therapeutics plc (STX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.303x

Based on the latest financial reports, Shield Therapeutics plc (STX) has a cash flow conversion efficiency ratio of 0.303x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.49 Million ≈ $-546.85 USD) by net assets (GBX-14.86 Million ≈ $-1.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Shield Therapeutics plc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Shield Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shield Therapeutics plc total liabilities for a breakdown of total debt and financial obligations.

Shield Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shield Therapeutics plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Thiensurat Public Company Limited BK:TSR	-0.011x
Value & Income Trust LSE:VIP	0.013x
Trifast plc LSE:TRI	0.049x
Inspecs Group plc LSE:SPEC	0.071x
Protagenic Therapeutics NASDAQ:PTIX	0.087x
BEACN Wizardry & Magic Inc V:BECN	-1.349x
Total Helium Ltd V:TOH	0.006x
AfriTin Mining Ltd LSE:ATM	-0.033x

Annual Cash Flow Conversion Efficiency for Shield Therapeutics plc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Shield Therapeutics plc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Shield Therapeutics plc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX-1.05 Million ≈ $-127.95	GBX-7.01 Million ≈ $-852.49	6.663x	+500.42%
2023-12-31	GBX22.31 Million ≈ $2.71K	GBX-37.13 Million ≈ $-4.52K	-1.664x	+50.51%
2022-12-31	GBX5.43 Million ≈ $660.31	GBX-18.25 Million ≈ $-2.22K	-3.362x	-724.25%
2021-12-31	GBX41.03 Million ≈ $4.99K	GBX-16.74 Million ≈ $-2.04K	-0.408x	-782.15%
2020-12-31	GBX30.28 Million ≈ $3.68K	GBX-1.40 Million ≈ $-170.34	-0.046x	+63.44%
2019-12-31	GBX32.15 Million ≈ $3.91K	GBX-4.07 Million ≈ $-494.71	-0.126x	-2773.01%
2018-12-31	GBX40.43 Million ≈ $4.92K	GBX-178.00K ≈ $-21.66	-0.004x	+98.88%
2017-12-31	GBX41.21 Million ≈ $5.01K	GBX-16.15 Million ≈ $-1.97K	-0.392x	-84.95%
2016-12-31	GBX48.40 Million ≈ $5.89K	GBX-10.26 Million ≈ $-1.25K	-0.212x	-194.45%
2015-12-31	GBX-18.64 Million ≈ $-2.27K	GBX-4.18 Million ≈ $-508.95	0.224x	+22.79%
2014-12-31	GBX-18.28 Million ≈ $-2.22K	GBX-3.34 Million ≈ $-406.50	0.183x	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$1.03 Million

GBX8.44 Billion GBX

Market Cap Rank

#30185 Global

#795 in UK

Share Price

GBX7.90

Change (1 day)

-9.71%

52-Week Range

GBX2.35 - GBX12.20

All Time High

GBX185.02